for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Verastem Inc

VSTM.OQ

Latest Trade

1.32USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.83

 - 

4.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.32
Open
--
Volume
--
3M AVG Volume
32.39
Today's High
--
Today's Low
--
52 Week High
4.80
52 Week Low
0.83
Shares Out (MIL)
74.35
Market Cap (MIL)
98.14
Forward P/E
-0.67
Dividend (Yield %)
--

Latest Developments

More

Verastem's Phase 2 PRIMO Study Data Evaluating Duvelisib In Relapsed Or Refractory Peripheral T-Cell Lymphoma

Verastem Oncology Reports Third Quarter Loss Per Share Of $0.41

Verastem Oncology Receives Orphan Drug Designation From FDA For Copiktra

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Verastem Inc

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.

Industry

Biotechnology & Drugs

Contact Info

117 Kendrick St Ste 500

+1.781.2924200

http://www.verastem.com/

Executive Leadership

Daniel W. Paterson

President, Chief Operating Officer

Brian M. Stuglik

Chief Executive Officer, Director

Robert E. Gagnon

Chief Financial Officer, Chief Business Officer

Steven Bloom

Chief Strategy Officer

Joseph M. Lobacki

Chief Commercial Officer

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.990

2017

-1.760

2018

-1.120

2019(E)

-1.978
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.52
Price To Book (MRQ)
4.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
632.67
LT Debt To Equity (MRQ)
632.67
Return on Investment (TTM)
-84.69
Return on Equity (TTM)
-65.77

Latest News

Latest News

BRIEF-Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per Share

* VERASTEM ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Verastem Oncology Announces Public Offering Of Common Stock

* VERASTEM ONCOLOGY ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41

* VERASTEM ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Verastem Reports Year-End 2017 Financial Results

* VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2 2018 Source text for Eikon: Further company coverage:

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

BRIEF-Verastem Announces Increased Hercules Debt Facility

* VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC

BRIEF-Verastem Announces Pricing Of Public Offering Of Common Stock

* VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Verastem Announces Public Offering Of Common Stock

* VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​

* VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY

BRIEF-Verastem reports Q3 loss per share of $0.61

* Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S

BRIEF-Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​

* Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

BRIEF-Verastem announces positive top-line data from the pivotal phase 3 Duo study

* Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

BRIEF-Ridgeback Capital Investments reports 7.7 pct passive stake in Verastem

* Ridgeback Capital Investments Lp reports a 7.7 percent passive stake in Verastem inc as of July 10, 2017 - sec filing Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up